Weekly Top News – Breast Cancer – April 22, 2019

April 22, 2019

Kisqali (ribociclib) / Novartis
In-depth gene expression analysis of premenopausal patients with HR+/HER2 advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial. (ASCO 2019) – Apr 21, 2019 – Abstract #1018; Pres time: Jun 2, 2019; 08:00 AM – 11:00 AM; Location: Poster Board: 99, Hall A; No abstract available.
Clinical • P3 data

 

Kadcyla (ado-trastuzumab emtansine) / Roche; Perjeta (pertuzumab) / Roche
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study). (ASCO 2019) – Apr 21, 2019 – Abstract #TPS1100; Pres time: Jun 2, 2019; 08:00 AM – 11:00 AM; Location: Poster Board: 181a, Hall A; No abstract available.
Clinical • P3 data

 

Afinitor (everolimus) / Novartis
Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: final results of the Phase III randomized MAIN-A trial (ESMO-BC 2019) – Apr 18, 2019 – Abstract #LBA2; Pres time: May 3, 2019; 05:30 PM – 05:45 PM; Location: Maritim Hall; No abstract available.
Clinical • Late-breaking abstract • P3 data

 

Herceptin (trastuzumab) / Roche; Perjeta (pertuzumab) / Roche
End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). (ASCO 2019) – Apr 21, 2019 – Abstract #1020; Pres time: Jun 2, 2019; 08:00 AM – 11:00 AM; Location: Poster Board: 101, Hall A; No abstract available.
Clinical • P3 data

 

cisplatin/vinblastine formulation with cell penetration enhancer (INT230-6) / Intensity Therap
Intensity Therapeutics receives Fast Track Designation from U.S. FDA for development of INT230-6 as treatment for relapsed or metastatic triple negative breast cancer (GlobeNewswire) – Apr 17, 2019 – “Intensity Therapeutics…announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s development program evaluating INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer (TNBC) who have failed at least two prior lines of therapy….’we look forward to working closely with the FDA this year to initiate a Phase 2 clinical study for this indication.’”
Fast track designation • New P2 trial

 

Ibrance (palbociclib) / Pfizer
ROIS: UK Ibrance Patient Program (IPP) Study (clinicaltrials.gov) – Apr 19, 2019 – P; N=250; Not yet recruiting; Sponsor: Pfizer
Clinical • New trial

No Comments

Post a Comment

Comment
Name
Email
Website